Docoh
Loading...

AIM AIM ImmunoTech

Press releases

From Benzinga Pro
AIM ImmunoTech to Participate in a Solve M.E. Diagnostics and Treatments Webinar
26 Jan 22
News, Press Releases
AIM ImmunoTech management to participate in webinar Thursday, January 27th from 2:00 pm - 3:00 pm ET Company to discuss clinical plans for investigational drug Ampligen for the treatment of myalgic
AIM ImmunoTech to Present at the Virtual Investor 2022 Top Picks Conference
19 Jan 22
News, Health Care, Press Releases
OCALA, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
12 Jan 22
Events, Press Releases
- Access the event and schedule of presenting companies at virtualinvestorco.com -- Live video webcast presentations of participating companies followed by interactive Q&A session -PITTSTOWN, NJ / ACCESSWIRE /
AIM ImmunoTech's Ampligen Safety Data Presented at Eighth European Scientific Working Group on Influenza
9 Dec 21
Health Care, Press Releases
OCALA, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) today announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific Working Group on Influenza
AIM ImmunoTech CEO to Participate in Two Upcoming Investor Conferences
6 Dec 21
News, Press Releases
OCALA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) today announced that Thomas Equels, Chief Executive Officer of AIM, will be participating in two upcoming investor conferences.
AIM ImmunoTech Provides Third Quarter 2021 Business Update
16 Nov 21
Earnings, Press Releases
OCALA, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) announces financial results for the third quarter ended September 30, 2021 and provides a business update. Third Quarter 2021